International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma

▤ Summary

This article highlights how international regulatory approvals can accelerate drug development across biotech and pharma. It uses NeOnc Technologies’ Abu Dhabi IND authorization for NEO212 as the core example and compares it with outcomes for Lilly, Biogen, and BridgeBio. The piece argues that early regulatory progress in multiple jurisdictions can support later FDA review, broader clinical development, and eventual commercialization. It also notes that NEO212 still faces substantial clinical, regulatory, and manufacturing hurdles before any launch is possible.

▦ Linked Companies